We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

Fund managers haven’t disclosed any holdings of MTNB yet.

MTNB Hedge Fund Activity: Q1 2026 in Review

28 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2026, worth a combined $177K — down 32% from $260K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MTNB positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 7 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $5.76K. The largest seller was DRW Securities, exiting entirely with an estimated $27.2K sold.

  • 28 institutional investors held Matinas BioPharma (MTNB) as of Q1 2026, down from 30 in Q4 2025.
  • Funds reported $177K of Matinas BioPharma stock for Q1 2026, down 32% quarter-over-quarter.
  • 5 funds opened new Matinas BioPharma positions in Q1 2026 and 4 closed out, a net change of +1 holder.
  • The largest Matinas BioPharma buyer in Q1 2026 was Geode Capital Management, an estimated $5.76K added.
  • The largest Matinas BioPharma seller in Q1 2026 was DRW Securities, an estimated $27.2K sold.

Based on aggregated 13F filings for Q1 2026.